Headache News and Research

Latest Headache News and Research

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.

1 Oct 2018

Measures to predict and prevent carbon monoxide poisoning after storm

Severe weather events, such as summer hurricanes, tornadoes, and winter snow storms often result in widespread and prolonged power outages, interrupting essential household functions, including home heating.

27 Sep 2018

Third case of monkey pox confirmed in UK

Officials from Public Health England (PHE) have confirmed yesterday (26th September 2018) that a third person in UK has been diagnosed with monkey pox. While the first two patients had most likely picked up the infection from Nigeria, this third infection has occurred in a healthcare worker who was treating one of the first two infected patients at Blackpool Victoria Hospital.

26 Sep 2018

Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD

Alexion Pharmaceuticals, Inc. today announced positive topline results from the Phase 3 PREVENT study of Soliris in patients with anti-aquaporin-4 auto antibody-positive neuromyelitis optica spectrum disorder.

24 Sep 2018

Biogen and Eisai announce results of LTE Phase 1b study of aducanumab for treating MCI

Biogen and Eisai Co., Ltd. announced results from a recent analysis of the ongoing long-term extension Phase 1b study of aducanumab, an investigational treatment for mild cognitive impairment due to Alzheimer's disease and mild AD dementia.

24 Sep 2018

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

Takeda Pharmaceutical Company Limited today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the full approval of ALUNBRIG® as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer previously treated with crizotinib.

24 Sep 2018

CHMP issues positive opinion supporting use of Trelegy Ellipta in broader group of COPD patients

GlaxoSmithKline plc and Innoviva, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion today supporting the use of Trelegy Ellipta in a broader group of patients with moderate to severe chronic obstructive pulmonary disease and that labeling, if approved, will be updated to further reflect its effect on exacerbations of COPD.

21 Sep 2018

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

Exelixis, Inc. today announced that its partner Ipsen Biopharmaceuticals Canada Inc. received approval from Health Canada of CABOMETYX® tablets for the treatment of adults with advanced renal cell carcinoma who have received prior vascular endothelial growth factor targeted therapy.

19 Sep 2018

FDA approves Teva’s AJOVY injection for preventive treatment of migraine in adults

Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has approved AJOVY injection for the preventive treatment of migraine in adults.

17 Sep 2018

Most parents aren't able to recognize meningitis until it's too late

New research commissioned by GSK has shown that the majority of parents incorrectly think that a rash or stiff neck are the first signs of meningitis.

14 Sep 2018

FDA approves new treatment for people with hairy cell leukemia

AstraZeneca and MedImmune, its global biologics research and development arm, announced today that the US Food and Drug Administration has approved LUMOXITI (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukemia who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

14 Sep 2018

Novel treatment for hairy cell leukemia approved by FDA

The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

14 Sep 2018

Second case of Monkeypox infection identified in UK

United Kingdom has recorded the second cases of Monekypox within days of the first case. This second case was a patient who tested positive for the virus at Blackpool Victoria Hospital.

12 Sep 2018

Medical cannabis provides relief across dozens of health symptoms, study shows

Utilizing new mobile application technology, researchers at The University of New Mexico found that medical cannabis provides immediate symptom relief across dozens of health symptoms with relatively minimal negative side effects.

11 Sep 2018

FDA approves Cassipa sublingual film for maintenance treatment of opioid dependence

The U.S. Food and Drug Administration today approved Cassipa (buprenorphine and naloxone) sublingual film (applied under the tongue) for the maintenance treatment of opioid dependence.

7 Sep 2018

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

Exelixis, Inc. today announced that the National Comprehensive Cancer Network updated its Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets.

7 Sep 2018

Phase 1 clinical trial examining topical cream plus influenza vaccine is underway

A Phase 1 clinical trial examining whether a topical cream can enhance the immune response conferred by a "pre-pandemic" influenza vaccine is underway at Baylor College of Medicine in Houston.

6 Sep 2018

Shionogi launches Mulpleta in the U.S for safe, effective treatment of thrombocytopenia

Shionogi & Co., Ltd. announced today that Mulpleta (lusutrombopag), a once-daily, orally administered, small molecule thrombopoietin (TPO) receptor agonist for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure, is now available throughout the United States.

30 Aug 2018

FDA accepts Bristol-Myers Squibb’s application for Sprycel for treating pediatric leukemia

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration accepted its supplemental Biologics License Application for Sprycel (dasatinib) in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

30 Aug 2018

EC grants marketing authorization for ONPATTRO (patisiran) in Europe

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that the European Commission (EC) has granted marketing authorization for ONPATTRO (patisiran) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults with stage 1 or stage 2 polyneuropathy.

30 Aug 2018

Headache News and Research

Latest Headache News and Research

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Measures to predict and prevent carbon monoxide poisoning after storm

Third case of monkey pox confirmed in UK

Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD

Biogen and Eisai announce results of LTE Phase 1b study of aducanumab for treating MCI

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

CHMP issues positive opinion supporting use of Trelegy Ellipta in broader group of COPD patients

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

FDA approves Teva’s AJOVY injection for preventive treatment of migraine in adults

Most parents aren't able to recognize meningitis until it's too late

FDA approves new treatment for people with hairy cell leukemia

Novel treatment for hairy cell leukemia approved by FDA

Second case of Monkeypox infection identified in UK

Medical cannabis provides relief across dozens of health symptoms, study shows

FDA approves Cassipa sublingual film for maintenance treatment of opioid dependence

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

Phase 1 clinical trial examining topical cream plus influenza vaccine is underway

Shionogi launches Mulpleta in the U.S for safe, effective treatment of thrombocytopenia

FDA accepts Bristol-Myers Squibb’s application for Sprycel for treating pediatric leukemia

EC grants marketing authorization for ONPATTRO (patisiran) in Europe

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Headache News and Research

Latest Headache News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in